{"entity":{"id":"drug-response-splits","kind":"term","name":"Drug-response data splits: leave-cell-line-out, leave-drug-out, leave-tissue-out","aka":["leave-cell-line-out","LCO split","leave-drug-out","LDO split","leave-tissue-out","LTO split","leave-pair-out","random pair split","cross-study validation"],"tldr":"How a drug-response dataset is split decides what a model's accuracy means: hold out cell lines to test personalised prediction, hold out drugs to test drug design, hold out tissues to test repurposing; holding out random pairs only tests imputation.","summary":"Bernett and colleagues' DrEval framework evaluates drug-response prediction models under explicit protocols, holding out cell lines, drugs or tissues so that a model is scored on the generalisation it claims, and finds that many published gains shrink under the harder splits. Training on one screen and testing on another (cross-study validation) is the sternest bar because assays, cell-line panels and summary statistics differ. Random pair splits leak both the cell line and the drug into training and should only support imputation claims.","asOf":"2026-09-24","links":[{"label":"Bernett et al., Critical evaluation of drug response prediction models with DrEval (Nature Communications 2026)","url":"https://doi.org/10.1038/s41467-026-72903-w"}],"tags":["cansim-terms"],"related":["cancer-ai-vocabulary"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["data-leakage","drug-response-baselines","drug-response-sensitivity","external-validation"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Listed in the CanSim terms map 1.0.0 (docs/onco/terms.json, generated 2026-09-24), CC BY 4.0, attribution: CanSim project, an open, public-data-first cancer foundation-model programme; CanSim page path /terms/leave-cell-line-out."],"provenance":{"editedBy":"OnCo CanSim terms wave (Wikipedia summaries, standards and project pages, GDC and FDA pages, Europe PMC)","editedOn":"2026-09-24","note":"CanSim terms map 1.0.0 (docs/onco/terms.json, generated 2026-09-24), CC BY 4.0, attribution: CanSim project, an open, public-data-first cancer foundation-model programme"},"category":"Methods and models"},"route":"/terms/drug-response-splits/","neighbours":{"term":[{"id":"cancer-ai-vocabulary","kind":"term","name":"Cancer AI vocabulary (CanSim terms map)","route":"/terms/cancer-ai-vocabulary/"},{"id":"data-leakage","kind":"term","name":"Data leakage in model evaluation","route":"/terms/data-leakage/"},{"id":"drug-response-sensitivity","kind":"term","name":"Drug response and drug sensitivity (IC50, AUC)","route":"/terms/drug-response-sensitivity/"},{"id":"drug-response-baselines","kind":"term","name":"Drug-response baselines and frameworks: mean-drug floor, LightGBM, DrEval, IMPROVE, DeepTTA","route":"/terms/drug-response-baselines/"},{"id":"external-validation","kind":"term","name":"External validation","route":"/terms/external-validation/"}]}}